- In March 2025, Abbott received the CE Mark in Europe for its Volt PFA System, a groundbreaking technology designed for the treatment of atrial fibrillation. This milestone marks a significant advancement in electrophysiology across Europe, underscoring Abbott’s commitment to enhancing treatment options for cardiac arrhythmias. This development is highly relevant to the global ablation devices market, as the Volt PFA System represents a significant innovation in the treatment of atrial fibrillation, a condition with a growing global prevalence
- In September 2024, Boston Scientific Corporation announced receiving approval from Japan’s Pharmaceuticals and Medical Device Agency (PMDA) for its FARAPULSE Pulsed Field Ablation (PFA) System. The system, indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation (AF), offers a novel alternative to traditional thermal ablation methods. The approval of the FARAPULSE PFA System is highly pertinent to the global ablation devices market, as it introduces an innovative, non-thermal ablation technology that enhances treatment options for atrial fibrillation, a prevalent cardiac arrhythmia
- In March 2023, Medtronic announced receiving CE Mark approval for its Affera Mapping and Ablation System, which includes the Sphere-9 Catheter and the Affera Prism-1 Mapping Software, designed for the treatment of atrial arrhythmias. This approval signifies a major advancement in the treatment of cardiac arrhythmias, enhancing Medtronic’s position in the European market. The introduction of the Affera Mapping and Ablation System is highly relevant to the global ablation devices market, as it represents the growing trend toward more precise, effective, and minimally invasive technologies in electrophysiology
- In October 2022, PENTAX Medical, a leading provider of diagnostic and therapeutic endoscopy solutions, announced the launch of the C2 CryoBalloon Ablation System in Canada for the treatment of Barrett's Esophagus. This innovative system offers a novel approach to managing this precancerous condition, enhancing the company’s presence in the gastrointestinal therapeutic space. The introduction of the C2 CryoBalloon Ablation System is highly relevant to the global ablation devices market, as it expands the application of ablation technologies beyond traditional cardiac and oncological uses to include gastrointestinal disorders
- In August 2022, Medtronic plc, a global leader in healthcare technology, announced the acquisition of Affera, Inc. This strategic acquisition enhanced Medtronic’s cardiac ablation portfolio by introducing its first-ever cardiac mapping and navigation platform, which includes a fully integrated solution combining diagnostic capabilities, focal pulsed field, and radiofrequency ablation technologies. This acquisition is highly relevant to the global ablation devices market, as it strengthens Medtronic’s portfolio with advanced, integrated technologies aimed at improving the precision and efficacy of cardiac arrhythmia treatments
